Dr. Reddy's Laboratories Ltd
corporate_fare Company Profile
Dr. Reddy's Laboratories Ltd (NYSE:RDY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for RDY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 11 rated 8 or above. Recent SEC coverage for RDY spans 6-K, 144, 20-F.
Recent high-impact activity:
- Dr. Reddy's Secures Brazil Approval for Generic Semaglutide Injection
- FDA Approves First Generic Rival to Gilead's Yeztugo
- Dr. Reddy's CEO Erez Israeli Notices Sale of 460,726 ADRs (~$6.5M)
- Dr. Reddy's Q2 FY2026 Profit Falls 36% on North America Price Erosion
- Third USFDA Form 483 in a Week Hits Dr. Reddy's, This Time at FTO-9 Facility
Financial Snapshot
Short Interest & Short Volume
7.81 days to coverFINRA reported short interest of 25,297,771 shares in RDY as of the October 30, 2026 settlement, a 3.2% decrease from the prior period — about 7.8 days to cover at its recent average daily volume. On November 20, 2026, 58.7% of RDY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
RDY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.